US Patent

US11124526 — Crystalline beta-lactamase inhibitor

Method of Use · Assigned to Allecra Therapeutics SAS · Expires 2034-11-07 · 8y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a crystalline compound that is a beta-lactamase inhibitor, which can be used in combination with an antibacterial agent.

USPTO Abstract

A crystalline compound of formula (I):The compound of formula (I) is a Î²-lactamase inhibitor and may be administered in combination with an antibacterial agent for prevention or treatment of bacterial infection.

Drugs covered by this patent

chembl-chembl1200962 (CEFEPIME HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3852`	—	chembl-chembl1200962

Patent Metadata

Patent number: US11124526
Jurisdiction: US
Classification: Method of Use
Expires: 2034-11-07
Drug substance claim: No
Drug product claim: No
Assignee: Allecra Therapeutics SAS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.